Paying users zone. Data is hidden behind hidden.

  • Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or

  • get full access to the entire website for at least 3 months from $49.99.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Microsoft Excel LibreOffice Calc

Bristol-Myers Squibb Co. (BMY)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Beginner level

Bristol-Myers Squibb Co., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Short-term debt obligations
Accounts payable
Rebates and returns
Employee compensation and benefits
Research and development
Dividends
Royalties
Branded Prescription Drug Fee
Liabilities related to assets held-for-sale
Litigation and other settlements
Restructuring
Pension and postretirement benefits
Other
Accrued liabilities
Deferred income
Income taxes payable
Current liabilities
Deferred income
Income taxes payable
Pension and other liabilities
Long-term debt, excluding current portion
Non-current liabilities
Total liabilities
Preferred stock, $2 convertible series, par value $1 per share
Common stock, par value of $0.10 per share
Capital in excess of par value of stock
Accumulated other comprehensive loss
Retained earnings
Cost of treasury stock
Total Bristol-Myers Squibb Company shareholders’ equity
Noncontrolling interest
Total equity
Total liabilities and equity

Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Bristol-Myers Squibb Co.’s current liabilities as a percentage of total liabilities and equity increased from 2016 to 2017 and from 2017 to 2018.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Bristol-Myers Squibb Co.’s non-current liabilities as a percentage of total liabilities and equity increased from 2016 to 2017 but then slightly decreased from 2017 to 2018 not reaching 2016 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Bristol-Myers Squibb Co.’s total liabilities as a percentage of total liabilities and equity increased from 2016 to 2017 but then slightly decreased from 2017 to 2018.
Total Bristol-Myers Squibb Company shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Bristol-Myers Squibb Co.’s total Bristol-Myers Squibb Company shareholders’ equity as a percentage of total liabilities and equity decreased from 2016 to 2017 but then slightly increased from 2017 to 2018.